Drug Combination Details
| General Information of the Combination (ID: C23303) | |||||
|---|---|---|---|---|---|
| Name | Daunorubicin NP Info | + | Rapamycin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
RAPA effectively eliminated this deleterious side effect of DNR, which might enhance DNR's ability to kill drug-resistant cancer. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line. Hematol Oncol. 2012 Sep;30(3):123-30. | |||
